{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T15:01:45Z","timestamp":1778770905593,"version":"3.51.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Phrapokklao Medical Education Center","award":["0033.105.3\/900"],"award-info":[{"award-number":["0033.105.3\/900"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess whether increasing radioactive iodine dose can increase treatment efficacy in Graves\u2019 disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A prospective study was conducted, including 106 patients receiving 20 mCi (740 MBq) radioactive iodine (RAI), compared with a retrospective data, including 113 patients receiving 10\u201315 mCi (370\u2013555 MBq) RAI. Remission and failure rates were evaluated at 6 months post-RAI. Statistical analysis was performed using logistic regression and Kaplan\u2013Meier curves.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Patients receiving 20 mCi RAI demonstrated a significantly higher remission rate compared to the 10\u201315 mCi group (82.1% vs 66.4%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.009). Median time to remission was shorter in the 20 mCI group (3 vs 4 months,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002). Hypothyroidism at 6 months was more prevalent in the 20 mCi group (67% vs 53%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03). Larger thyroid size (&gt;\u200960 g) was associated with treatment failure (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Higher dosage (20 mCi) RAI showed superior efficacy in achieving remission compared to lower dosages (10\u201315 mCi) in Graves\u2019 disease treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12902-024-01588-3","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T06:02:19Z","timestamp":1714024939000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prospective study to evaluate radioactive iodine of 20 mCi vs 10\u201315 mCi in Graves\u2019 disease"],"prefix":"10.1186","volume":"24","author":[{"given":"Wasit","family":"Kanokwongnuwat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nawarat","family":"Penpong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,25]]},"reference":[{"issue":"15","key":"1588_CR1","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1001\/jama.2023.19052","volume":"330","author":"SY Lee","year":"2023","unstructured":"Lee SY, Pearce EN. Hyperthyroidism: A Review. JAMA. 2023;330(15):1472\u201383.","journal-title":"JAMA"},{"issue":"4","key":"1588_CR2","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/S2213-8587(23)00005-0","volume":"11","author":"WM Wiersinga","year":"2023","unstructured":"Wiersinga WM, Poppe KG, Effraimidis G. Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis. Lancet Diabetes Endocrinol. 2023;11(4):282\u201398.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"1588_CR3","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1530\/EJE-09-0286","volume":"161","author":"A de Rooij","year":"2009","unstructured":"de Rooij A, Vandenbroucke JP, Smit JW, Stokkel MP, Dekkers OM. Clinical outcomes after estimated versus calculated activity of radioiodine for the treatment of hyperthyroidism: systematic review and meta-analysis. Eur J Endocrinol. 2009;161(5):771\u20137.","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"1588_CR4","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1089\/thy.2016.0229","volume":"26","author":"DS Ross","year":"2016","unstructured":"Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016;26(10):1343\u2013421.","journal-title":"Thyroid"},{"issue":"3","key":"1588_CR5","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/RLU.0b013e31823ea6e0","volume":"37","author":"RB Santos","year":"2012","unstructured":"Santos RB, Romaldini JH, Ward LS. A randomized controlled trial to evaluate the effectiveness of 2 regimens of fixed iodine ((1)(3)(1)I) doses for Graves disease treatment. Clin Nucl Med. 2012;37(3):241\u20134.","journal-title":"Clin Nucl Med"},{"issue":"2","key":"1588_CR6","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1089\/105072502753522365","volume":"12","author":"M Braga","year":"2002","unstructured":"Braga M, Walpert N, Burch HB, Solomon BL, Cooper DS. The effect of methimazole on cure rates after radioiodine treatment for Graves\u2019 hyperthyroidism: a randomized clinical trial. Thyroid. 2002;12(2):135\u20139.","journal-title":"Thyroid"},{"issue":"3","key":"1588_CR7","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1089\/thy.2019.0132","volume":"30","author":"JP Brito","year":"2020","unstructured":"Brito JP, Payne S, Singh Ospina N, Rodriguez-Gutierrez R, Maraka S, Sangaralingham LR, et al. Patterns of Use, Efficacy, and Safety of Treatment Options for Patients with Graves\u2019 Disease: A Nationwide Population-Based Study. Thyroid. 2020;30(3):357\u201364.","journal-title":"Thyroid"},{"issue":"1","key":"1588_CR8","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/cen.13873","volume":"90","author":"ET Aung","year":"2019","unstructured":"Aung ET, Zammitt NN, Dover AR, Strachan MWJ, Seckl JR, Gibb FW. Predicting outcomes and complications following radioiodine therapy in Graves\u2019 thyrotoxicosis. Clin Endocrinol (Oxf). 2019;90(1):192\u20139.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"1588_CR9","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1097\/MNM.0000000000001138","volume":"41","author":"H Park","year":"2020","unstructured":"Park H, Kim HI, Park J, Park SY, Kim TH, Chung JH, et al. The success rate of radioactive iodine therapy for Graves\u2019 disease in iodine-replete area and affecting factors: a single-center study. Nucl Med Commun. 2020;41(3):212\u20138.","journal-title":"Nucl Med Commun"},{"issue":"3","key":"1588_CR10","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3803\/EnM.2022.1418","volume":"37","author":"MJ Kim","year":"2022","unstructured":"Kim MJ, Cho SW, Kim YA, Choi HS, Park YJ, Park DJ, et al. Clinical Outcomes of Repeated Radioactive Iodine Therapy for Graves\u2019 Disease. Endocrinol Metab (Seoul). 2022;37(3):524\u201332.","journal-title":"Endocrinol Metab (Seoul)"},{"key":"1588_CR11","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/958276","volume":"2013","author":"JM Dora","year":"2013","unstructured":"Dora JM, Escouto Machado W, Andrade VA, Scheffel RS, Maia AL. Increasing the radioiodine dose does not improve cure rates in severe graves\u2019 hyperthyroidism: a clinical trial with historical control. J Thyroid Res. 2013;2013: 958276.","journal-title":"J Thyroid Res"},{"issue":"1","key":"1588_CR12","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12902-018-0322-7","volume":"18","author":"E Fanning","year":"2018","unstructured":"Fanning E, Inder WJ, Mackenzie E. Radioiodine treatment for graves\u2019 disease: a 10-year Australian cohort study. BMC Endocr Disord. 2018;18(1):94.","journal-title":"BMC Endocr Disord"},{"issue":"9","key":"1588_CR13","doi-asserted-by":"publisher","first-page":"4439","DOI":"10.1210\/jc.2004-0247","volume":"89","author":"SJ Bonnema","year":"2004","unstructured":"Bonnema SJ, Bennedbaek FN, Veje A, Marving J, Hegedus L. Propylthiouracil before 131I therapy of hyperthyroid diseases: effect on cure rate evaluated by a randomized clinical trial. J Clin Endocrinol Metab. 2004;89(9):4439\u201344.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1588_CR14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1089\/thy.1995.5.7","volume":"5","author":"AW Kung","year":"1995","unstructured":"Kung AW, Yau CC, Cheng AC. The action of methimazole and L-thyroxine in radioiodine therapy: a prospective study on the incidence of hypothyroidism. Thyroid. 1995;5(1):7\u201312.","journal-title":"Thyroid"},{"issue":"10","key":"1588_CR15","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1089\/thy.2011.0362","volume":"22","author":"S Sztal-Mazer","year":"2012","unstructured":"Sztal-Mazer S, Nakatani VY, Bortolini LG, Boguszewski CL, Graf H, de Carvalho GA. Evidence for higher success rates and successful treatment earlier in Graves\u2019 disease with higher radioactive iodine doses. Thyroid. 2012;22(10):991\u20135.","journal-title":"Thyroid"},{"issue":"3","key":"1588_CR16","first-page":"411","volume":"32","author":"RA Nordyke","year":"1991","unstructured":"Nordyke RA, Gilbert FI Jr. Optimal iodine-131 dose for eliminating hyperthyroidism in Graves\u2019 disease. J Nucl Med. 1991;32(3):411\u20136.","journal-title":"J Nucl Med"},{"issue":"6","key":"1588_CR17","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/j.1365-2265.2004.02032.x","volume":"60","author":"CT He","year":"2004","unstructured":"He CT, Hsieh AT, Pei D, Hung YJ, Wu LY, Yang TC, et al. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves\u2019 hyperthyroidism. Clin Endocrinol (Oxf). 2004;60(6):676\u201381.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"7","key":"1588_CR18","doi-asserted-by":"publisher","first-page":"e0253590","DOI":"10.1371\/journal.pone.0253590","volume":"16","author":"S Chotivichien","year":"2021","unstructured":"Chotivichien S, Chongchaithet N, Aksornchu P, Boonmongkol N, Duangmusik P, Knowles J, et al. Assessment of the contribution of industrially processed foods to salt and iodine intake in Thailand. PLoS ONE. 2021;16(7):e0253590.","journal-title":"PLoS ONE"},{"issue":"1","key":"1588_CR19","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00394-017-1587-8","volume":"58","author":"HI Kim","year":"2019","unstructured":"Kim HI, Oh HK, Park SY, Jang HW, Shin MH, Kim SW, et al. Urinary iodine concentration and thyroid hormones: Korea National Health and Nutrition Examination Survey 2013\u20132015. Eur J Nutr. 2019;58(1):233\u201340.","journal-title":"Eur J Nutr"},{"issue":"3","key":"1588_CR20","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S0002-8223(01)00078-5","volume":"101","author":"P Trumbo","year":"2001","unstructured":"Trumbo P, Yates AA, Schlicker S, Poos M. Dietary reference intakes: vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc. J Am Diet Assoc. 2001;101(3):294\u2013301.","journal-title":"J Am Diet Assoc"},{"issue":"2","key":"1588_CR21","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.amjsurg.2021.03.068","volume":"223","author":"M Shalaby","year":"2022","unstructured":"Shalaby M, Hadedeya D, Toraih EA, Razavi MA, Lee GS, Hussein MH, et al. Predictive factors of radioiodine therapy failure in Graves\u2019 Disease: A meta-analysis. Am J Surg. 2022;223(2):287\u201396.","journal-title":"Am J Surg"},{"issue":"3","key":"1588_CR22","first-page":"1073","volume":"87","author":"EK Alexander","year":"2002","unstructured":"Alexander EK, Larsen PR. High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves\u2019 disease. J Clin Endocrinol Metab. 2002;87(3):1073\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"13","key":"1588_CR23","doi-asserted-by":"publisher","first-page":"4174","DOI":"10.1245\/s10434-014-3858-4","volume":"21","author":"DF Schneider","year":"2014","unstructured":"Schneider DF, Sonderman PE, Jones MF, Ojomo KA, Chen H, Jaume JC, et al. Failure of radioactive iodine in the treatment of hyperthyroidism. Ann Surg Oncol. 2014;21(13):4174\u201380.","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"1588_CR24","doi-asserted-by":"publisher","first-page":"3704","DOI":"10.1210\/clinem\/dgaa646","volume":"105","author":"GJ Kahaly","year":"2020","unstructured":"Kahaly GJ. Management of Graves Thyroidal and Extrathyroidal Disease: An Update. J Clin Endocrinol Metab. 2020;105(12):3704\u201320.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"1588_CR25","first-page":"3016","volume":"86","author":"HB Burch","year":"2001","unstructured":"Burch HB, Solomon BL, Cooper DS, Ferguson P, Walpert N, Howard R. The effect of antithyroid drug pretreatment on acute changes in thyroid hormone levels after (131)I ablation for Graves\u2019 disease. J Clin Endocrinol Metab. 2001;86(7):3016\u201321.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"1588_CR26","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1001\/jamainternmed.2019.0981","volume":"179","author":"CM Kitahara","year":"2019","unstructured":"Kitahara CM, Berrington de Gonzalez A, Bouville A, Brill AB, Doody MM, Melo DR, et al. Association of Radioactive Iodine Treatment With Cancer Mortality in Patients With Hyperthyroidism. JAMA Intern Med. 2019;179(8):1034\u201342.","journal-title":"JAMA Intern Med."},{"issue":"7","key":"1588_CR27","doi-asserted-by":"publisher","first-page":"e209660","DOI":"10.1001\/jamanetworkopen.2020.9660","volume":"3","author":"CM Kitahara","year":"2020","unstructured":"Kitahara CM, Preston DL, Sosa JA, Berrington de Gonzalez A. Association of Radioactive Iodine, Antithyroid Drug, and Surgical Treatments With Solid Cancer Mortality in Patients With Hyperthyroidism. JAMA Netw Open. 2020;3(7):e209660.","journal-title":"JAMA Netw Open."},{"issue":"9","key":"1588_CR28","doi-asserted-by":"publisher","first-page":"e2125072","DOI":"10.1001\/jamanetworkopen.2021.25072","volume":"4","author":"SR Shim","year":"2021","unstructured":"Shim SR, Kitahara CM, Cha ES, Kim SJ, Bang YJ, Lee WJ. Cancer Risk After Radioactive Iodine Treatment for Hyperthyroidism: A Systematic Review and Meta-analysis. JAMA Netw Open. 2021;4(9):e2125072.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"1588_CR29","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1089\/thy.2019.0205","volume":"30","author":"N Gronich","year":"2020","unstructured":"Gronich N, Lavi I, Rennert G, Saliba W. Cancer Risk After Radioactive Iodine Treatment for Hyperthyroidism: A Cohort Study. Thyroid. 2020;30(2):243\u201350.","journal-title":"Thyroid"},{"issue":"2","key":"1588_CR30","doi-asserted-by":"publisher","first-page":"e448","DOI":"10.1210\/clinem\/dgab700","volume":"107","author":"BW Kim","year":"2022","unstructured":"Kim BW. Does Radioactive Iodine Therapy for Hyperthyroidism Cause Cancer? J Clin Endocrinol Metab. 2022;107(2):e448\u201357.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-024-01588-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-024-01588-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-024-01588-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T06:05:57Z","timestamp":1714025157000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-024-01588-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,25]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1588"],"URL":"https:\/\/doi.org\/10.1186\/s12902-024-01588-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3972356\/v1","asserted-by":"object"}]},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,25]]},"assertion":[{"value":"20 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Chanthaburi Research Ethics Committee (COA032\/65). All experimental protocols were approved by Chanthaburi Research Ethics Committee. Informed consents were obtained from all subjects and\/or their legal guardian(s).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"54"}}